Biogen sues Teva over MS generic
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Virtual MS Medical Forum | Neurologybytes Events
Teva reports new Copaxone data in breastfeeding mothers with relapsing multiple sclerosis | Seeking Alpha
EU launches antitrust probe against Teva - www.israelhayom.com
Teva hires ex-Novartis executive to succeed CEO Schultz, HR News, ETHRWorld
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Teva tumbles as sales and earnings underwhelm
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
COPAXONE® | Medication to Treat Relapsing Multiple Sclerosis (RMS)
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Teva Pharma Plunges After Two U.S. Copaxone Patents Invalidated | Investor's Business Daily
Skinny labels' at forefront of possible Supreme Court biopharma cases | BioWorld
EU Probes Teva For Blocking Rivals To Multiple Sclerosis Drug
Teva offers generic Tecfidera | Drug Store News
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | Fierce Pharma
High-Court-Sides-Teva-Patent
Teva and Active Biotech Expand Investigational MS Treatment Program
Baclofen Tablets 20 mg by Teva 100 Count — Mountainside Medical Equipment
U.S. Court backs Teva multiple sclerosis drug patents | NASDAQ:TEVA
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Business Wire
